Doxorubicin Market could be worth US$ 1,983.40 million by 2028, says Premium Market Insights

Doxorubicin Market Forecast to 2028 - COVID-19 Impact and Global Analysis By Drug Formulation (Lyophilized Powder and Doxorubicin Injection), Application (Breast Cancer, Kidney Cancer, Liver Cancer, Sarcoma, Ovarian Cancer, Lung Cancer, Leukemia, Multiple Myeloma, and Others), and Distribution Channel (Hospital Pharmacy, Retail Pharmacy, and Online Pharmacy) The global doxorubicin market is projected to reach US$ 1,983.40 million by 2028 from US$ 1,390.64 million in 2022; it is expected to register a CAGR of 6.1% from 2022 to 2028.

Get PDF Sample Report + All Related Table and Graphs @: https://www.premiummarketinsights.com/sample/TIP00028146?utm_source=OpenPR&utm_medium=10823

Competitive Landscape: Doxorubicin Market:
Doxorubicin belongs to the anthracycline family and is widely used for the treatment of malignancies such as breast, lung, multiple myeloma, ovarian, kidney, liver, sarcoma, and others. The product is used in the patients with cancer whose disease has progressed or recurred after chemotherapy. Cancer is a leading cause of death globally. According to the World Health Organization (WHO), cancer was the first leading cause of death in people below 70 years in 183 countries and the fourth major cause of death among the population of all ages in 123 countries worldwide in 2019. In addition, as per the data published by the WHO in March 2021, different cancer types will have caused ~10 million deaths in 2020. The increasing prevalence of cancer has burdened healthcare systems worldwide, bolstering the demand for chemotherapy. Doxorubicin is one of the primary drugs used as first-line treatment in chemotherapy. The drug is used to cause regression in disseminated neoplastic diseases like breast, ovarian, transitional cell bladder, thyroid, gastric, acute lymphoblastic leukemia, acute myeloblastic leukemia, Wilms' tumor, neuroblastoma, soft tissue and bone sarcomas, Hodgkin's disease, malignant lymphoma, and bronchogenic carcinomas, in which the small cell histologic type. The drug is also recommended as adjuvant therapy in women who have had primary breast cancer removed and have axillary lymph node involvement.

Accord Healthcare
Cipla Inc.
Dr. Reddy's Laboratories
Meiji Holdings Co., Ltd.
Janssen Pharmaceuticals (Johnson and Johnson Services, Inc.)
Novartis AG
Pfizer Inc.
Sun Pharmaceutical Industries Ltd
Baxter International Inc.
Zydus Cadila
Bottom of Form

Chapter Details of Doxorubicin Market:
Part 01: Executive Summary
Part 02: Scope of The Report
Part 03: Doxorubicin Market Landscape
Part 04: Doxorubicin Market Sizing
Part 05: Doxorubicin Market Segmentation by Product
Part 06: Five Forces Analysis
Part 07: Customer Landscape
Part 08: Geographic Landscape
Part 09: Decision Framework
Part 10: Drivers and Challenges
Part 11: Market Trends
Part 12: Vendor Landscape
Part 13: Vendor Analysis

Interested in Purchasing this Report? Click here @ https://www.premiummarketinsights.com/buy/TIP00028146?utm_source=OpenPR&utm_medium=10823

Contact Us:
If you have any queries about this report or if you would like further information, please contact us:
Contact Person: Ankit Mathur
E-mail: sales@permiummarketinsights.com
Phone: +1-646-491-9876

About Us:
Premium Market Insights is a one stop shop of market research reports and solutions to various companies across the globe. We help our clients in their decision support system by helping them choose most relevant and cost effective research reports and solutions from various publishers.
The market research industry has changed in last decade. As corporate focus has shifted to niche markets and emerging countries, a number of publishers have stepped in to fulfil these information needs. We have experienced and trained staff that helps you navigate different options and lets you choose best research solution at most effective cost.

This release was published on openPR.